NEUROCRINE BIOSCIENCES INC (NBIX) Debt Components
- 2024-03-31: Debt Instrument, Face AmountUSD $170.40M; Debt Instrument, Unamortized DiscountUSD (m); Debt Instrument, Unamortized Discount (Premium), NetUSD (m).
- 2023-12-31: Debt Instrument, Face AmountUSD $170.40M; Debt Instrument, Unamortized DiscountUSD (m); Debt Instrument, Unamortized Discount (Premium), NetUSD (m).
- 2021-12-31: Debt Instrument, Face AmountUSD $381.20M; Debt Instrument, Unamortized DiscountUSD $43.20M; Debt Instrument, Unamortized Discount (Premium), NetUSD (m).
- 2021-09-30: Debt Instrument, Face AmountUSD $381.20M; Debt Instrument, Unamortized DiscountUSD (m); Debt Instrument, Unamortized Discount (Premium), NetUSD $47.30M.
NEUROCRINE BIOSCIENCES INC Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Debt Instrument, Face Amount USD | Debt Instrument, Unamortized Discount USD | Debt Instrument, Unamortized Discount (Premium), Net USD |
|---|---|---|---|
| 2024-03-31 | $170.40M | (m) | (m) |
| 2023-12-31 | $170.40M | (m) | (m) |
| 2021-12-31 | $381.20M | $43.20M | (m) |
| 2021-09-30 | $381.20M | (m) | $47.30M |
| 2021-06-30 | $381.20M | (m) | $51.50M |
| 2021-03-31 | $381.20M | (m) | $55.50M |
| 2020-12-31 | $381.30M | $59.40M | (m) |
| 2020-12-31 | (m) | (m) | $59.40M |
| 2020-09-30 | $517.50M | (m) | $86.60M |
| 2020-06-30 | $517.50M | (m) | $91.80M |
| 2020-03-31 | $517.50M | (m) | $96.80M |
| 2019-12-31 | $517.50M | $101.80M | (m) |
| 2019-12-31 | (m) | (m) | $101.80M |
| 2019-09-30 | $517.50M | (m) | $106.62M |
| 2019-06-30 | $517.50M | (m) | $111.39M |
| 2019-03-31 | $517.50M | (m) | $116.08M |
| 2018-12-31 | $517.50M | (m) | $120.68M |
| 2018-09-30 | $517.50M | (m) | $125.19M |
| 2018-06-30 | $517.50M | (m) | $129.62M |
| 2018-03-31 | $517.50M | (m) | $133.97M |
| 2017-12-31 | $517.50M | (m) | $138.23M |
| 2017-09-30 | $517.50M | (m) | $142.41M |
| 2017-06-30 | $517.50M | (m) | $146.52M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |